The consensus algorithm for the medical management of type 2 diabetes was published in
August 2006 with the expectation that it would be updated, based on the availability of new …

Moderate aLimited use in the US/Europe. bNot licensed in the US cPrescribing highly restricted
in the US; withdrawn in Europe. dNot licensed in Europe. eTo be available as a generic …

The term “metabolic syndrome” refers to a clustering of specific cardiovascular disease (CVD)
risk factors whose underlying pathophysiology is thought to be related to insulin resistance…

In 2012, the American Diabetes Association (ADA) and the European Association for the Study
of Diabetes (EASD) published a position statement on the management of hyperglycemia …

… Deckers, Michel Bertrand, Bernard Charbonnel, Erland Erdmann, Ele Ferrannini, Allan
Flyvbjerg, Helmut Gohlke, Jose Ramon Gonzalez Juanatey, Ian Graham, Pedro Filipe …

Type 2 diabetes mellitus (T2DM) is an expanding global health problem, closely linked to
the epidemic of obesity. Individuals with T2DM are at high risk for both microvascular …

Glycaemic management in type 2 diabetes mellitus has become increasingly complex and,
to some extent, controversial, with a widening array of pharmacological agents now available …

Insulin resistance and insulin hypersecretion are established features of obesity. Their
prevalence, however, has only been inferred from plasma insulin concentrations. We measured …

Background. Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing
urinary glucose excretion. The physiologic response to pharmacologically induced acute …

OBJECTIVE Dapagliflozin, a highly selective inhibitor of the renal sodium-glucose cotransporter-2,
increases urinary excretion of glucose and lowers plasma glucose levels in an insulin-…